Streetbeat News

Products Services

CASI

CASI Pharmaceuticals' shares surged following the announcement of positive interim Phase 1 data for BI-1206, aimed at treating relapsed/refractory indolent Non-Hodgkin's Lymphoma in China.

Portfolio Pulse from Benzinga Newsdesk

March 05, 2024 | 12:44 pm

BTCUSD

Bitwise Asset Management's CIO, Matt Hougan, predicts Bitcoin could exceed $200,000 in 2024 due to a significant supply-demand imbalance, particularly with the anticipated approval of spot Bitcoin ETFs. This revision from an initial $80,000 forecast is driven by growing demand from various investor groups and the upcoming halving event reducing new supply. Bitcoin's recent price surge to a new all-time high market cap of $1.33 trillion supports this bullish outlook.

Portfolio Pulse from Benzinga Neuro

March 05, 2024 | 12:44 pm

NVO

Novo Nordisk A/S announced that its diabetes medicine, Ozempic, significantly reduces the risk of kidney disease progression in type 2 diabetes and chronic kidney disease patients, according to the FLOW study results. The trial, which compared semaglutide 1.0 mg with placebo, achieved its primary endpoint, showing a 24% reduction in kidney disease progression, major adverse cardiovascular events, and death. Novo Nordisk plans to seek regulatory approvals for Ozempic's label expansion in the U.S. and EU in 2024. However, NVO shares dropped 1.79% in premarket trading.

Portfolio Pulse from Vandana Singh

March 05, 2024 | 12:41 pm

ALNY

RHHBY

Alnylam Pharmaceuticals and Roche reported that their KARDIA-2 study met its primary endpoint, showing significant blood pressure reductions with Zilebesiran when added to standard antihypertensive treatments.

Portfolio Pulse from Benzinga Newsdesk

March 05, 2024 | 12:41 pm

RGNX

REGENXBIO's stock price increased following the announcement of promising initial efficacy data from its AFFINITY DUCHENNE trial of RGX-202.

Portfolio Pulse from Benzinga Newsdesk

March 05, 2024 | 12:36 pm

GM

MGA

WIT

General Motors (GM), Magna (MGA), and Wipro Limited (WIT) have collaborated to create SDVerse, a B2B sales platform designed to transform the automotive software sourcing and procurement process by facilitating the buying and selling of embedded automotive software.

Portfolio Pulse from Benzinga Newsdesk

March 05, 2024 | 12:34 pm

APGE

Apogee Therapeutics' shares surged following the announcement of positive interim results from its Phase 1 trial of APG777 and the release of its FY23 financial results.

Portfolio Pulse from Benzinga Newsdesk

March 05, 2024 | 12:32 pm

GOOG

GOOGL

Alphabet Inc.'s Android Auto has updated to version 11.4, introducing a feature that locks certain apps, such as gaming and video streaming, while the vehicle is in motion. This update aims to promote safer driving by preventing access to these apps unless the car is parked, indicated by a 'P' icon. Additionally, Android Auto v11.4 can abbreviate long text messages to reduce distractions. This is part of Alphabet's broader effort to enhance user experience and promote seamless connectivity across Android devices, as announced at CES 2024.

Portfolio Pulse from Benzinga Neuro

March 05, 2024 | 12:23 pm

RDHL

Redhill Biopharma and Apogee Biotechnology's drug, Opaganib, has been selected by the U.S. Government's Chemical Medical Countermeasures Program and Chemical Countermeasures Research Program as a potential countermeasure against inhalation sulfur mustard exposure. This selection could lead to increased funding and support for further development and potential deployment of Opaganib.

Portfolio Pulse from Benzinga Newsdesk

March 05, 2024 | 12:21 pm

ABBV

Dragonfly Therapeutics has received a milestone payment after the first patient was dosed in a clinical trial by AbbVie. The trial is evaluating ABBV-303, a treatment targeting solid tumors. This development marks a significant step in the collaboration between Dragonfly Therapeutics and AbbVie, potentially impacting the progress and valuation of ABBV-303.

Portfolio Pulse from Benzinga Newsdesk

March 05, 2024 | 12:17 pm